Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020089432 - NEW PROGNOSTIC METHOD OF PANCREATIC CANCER

Publication Number WO/2020/089432
Publication Date 07.05.2020
International Application No. PCT/EP2019/079912
International Filing Date 31.10.2019
IPC
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2333/70596
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/57438
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57438of liver, pancreas or kidney
G01N 33/57488
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57484involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
57488involving compounds identifable in body fluids
Applicants
  • INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR]/[FR]
  • UNIVERSITÉ D'AIX MARSEILLE [FR]/[FR]
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) [FR]/[FR]
  • INSTITUT JEAN PAOLI & IRENE CALMETTES [FR]/[FR]
Inventors
  • OLIVE, Daniel
  • IOVANNA, Juan
  • DAGORN, Jean-Charles
Agents
  • INSERM TRANSFERT
Priority Data
18306440.102.11.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEW PROGNOSTIC METHOD OF PANCREATIC CANCER
(FR) NOUVELLE MÉTHODE DE PRONOSTIC DU CANCER DU PANCRÉAS
Abstract
(EN)
The present invention relates to a prognostic method of pancreatic cancer. In the present study, the inventors use specific antibodies to monitor the concentrations of soluble forms of PD-1 and PD-L1 in plasma of advanced PDAC patients, which are not eligible for resection, by ad hoc developed ELISAs. They showed that high plasma levels of these immune checkpoints correlate with poor outcome and can be used as prognostic factors in non-resectable PDAC. Thus the present invention relates to a method for predicting the survival time of a patient suffering from a pancreatic cancer comprising determining in a sample obtained from the patient the expression level of PD-1 and/or PD-L1.
(FR)
La présente invention concerne une méthode de pronostic du cancer du pancréas. Dans la présente étude, les inventeurs utilisent des anticorps spécifiques pour surveiller les concentrations de formes solubles de PD-1 et PD-L1 dans le plasma de patients souffrant d'adénocarcinome ductal pancréatique PDAC avancé, qui ne sont pas éligibles à une résection, par ELISA ad hoc développés. Ils ont démontré que des niveaux de plasma élevés de ces points de contrôle immunitaires sont corrélés avec un résultat médiocre et peuvent être utilisés en tant que facteurs de pronostic dans le PDAC non résécable. Ainsi, l'invention concerne une méthode de prédiction du temps de survie d'un patient souffrant d'un cancer du pancréas, comprenant la détermination dans un échantillon prélevé sur le patient, du taux d'expression de PD-1 et/ou de PD-L 1.
Latest bibliographic data on file with the International Bureau